The Journal of Clinical Endocrinology & Metabolism · 2007 · 131 citations · 16 references
MedicinePharmacotherapyBone AugmentationBone MetabolismHiv PreventionAntiretroviral TherapyBone HealthBone Metabolism PharmacotherapyMetabolic Bone DiseaseOsteoporosisBone Density EffectsBone Mineral DensityBone Mineral LossBone Turnover RateDrug Effects On Bone DensityHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyLow Bone Mineral Density
CONTEXT: Recent studies have reported low bone mineral density (BMD) in HIV-infected patients. Annual iv administration of 4 mg zoledronate has been shown to increase BMD and suppress bone turnover in postmenopausal women. OBJECTIVE: The objective of the study was to determine whether annual administration of 4 mg zoledronate will increase BMD in HIV-infected men receiving highly active antiretroviral therapy. DESIGN AND SETTING: A 2-yr randomized placebo-controlled trial was conducted in a clinical research center. PARTICIPANTS: A total of 43 HIV-infected men were treated with highly active antiretroviral therapy for at least 3 months, with BMD T score less than -0.5. INTERVENTION: Participants received annual iv administration of 4 mg zoledronate or placebo. All participants took 400 mg/d calcium and 1.25 mg/month vitamin D. MEASUREMENTS: BMD at the lumbar spine, total hip and total body, and bone turnover markers were measured. RESULTS: At the lumbar spine, BMD increased by 8.9% over 2 yr in the zoledronate group compared with an increase of 2.6% in the control group (P<0.001). At the total hip, BMD increased by 3.8% over 2 yr in the zoledronate group compared with a decrease of 0.8% in the control group (P<0.001). At the total body, BMD increased by 2.3% over 2 yr compared with a decrease of 0.5% in the control group (P<0.001). Urine N-telopeptide decreased by 60% at 3 months in the zoledronate group and thereafter remained stable. CONCLUSIONS: Annual administration of zoledronate is a potent and effective therapy for the prevention or treatment of bone loss in HIV-infected men. The current data provide the first trial evidence of the BMD effects of annual zoledronate beyond 1 yr in any population, as well as being the first reported trial in men.
16
Alendronate for the Treatment of Osteoporosis in Men
Eric Orwoll, Mark P. Ettinger, Stuart Weiss et al. · New England Journal of Medicine · 2000 · 977 citations · Full text
IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis
Ann Cranney, Gordon Guyatt, Lauren E. Griffith et al. · Endocrine Reviews · 2002 · 608 citations · Full text
Stephen F. Hodgson, Nelson B. Watts, John P. Bilezikian et al. · Endocrine Practice · 2003 · 606 citations